Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney ...

1. Oh YK, Park HC, Ryu H, Kim YC, Oh KH. Clinical and genetic characteristics of Korean autosomal dominant polycystic kidney disease patients. Korean J Intern Med 2021;36:767–779.
crossref pmid pmc pdf
2. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis 2016;67:792–810.
crossref pmid pmc
3. Jones TJ, Nauli SM. Mechanosensory calcium signaling. Adv Exp Med Biol 2012;740:1001–1015.
crossref pmid
4. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006;2:40–55quiz 55.
crossref pdf
5. Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE. Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol 2015;11:451–464.
crossref pmid pmc pdf
6. Bichet DG. Central vasopressin: dendritic and axonal secretion and renal actions. Clin Kidney J 2014;7:242–247.
crossref pmid pmc
7. Lee Y, Yoo KD, Baek SH, et al. Korean Society of Nephrology 2022 recommendations on controversial issues in diagnosis and management of hyponatremia. Korean J Intern Med 2022;37:1120–1137.
crossref pmid pmc pdf
8. Meijer E, Bakker SJ, van der Jagt EJ, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:361–368.
crossref pmid pmc
9. Baur BP, Meaney CJ. Review of tolvaptan for autosomal dominant polycystic kidney disease. Pharmacotherapy 2014;34:605–616.
crossref pmid pdf
10. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl – secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011;301:F1005–F1013.
crossref pmid pmc
11. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017;377:1930–1942.
crossref pmid
12. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407–2418.
crossref pmid pmc
13. Radhakrishnan Y, Duriseti P, Chebib FT. Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options. Kidney Res Clin Pract 2022;41:422–431.
crossref pmid pmc pdf
14. Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006;17:3013–3019.
crossref pmid
15. Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010;6:96–106.
crossref pmid pdf
16. Park HC, Hong Y, Yeon JH, et al. Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study. Kidney Res Clin Pract 2022;41:432–441.
crossref pmid pmc pdf
17. Jung Y. Using the Mayo imaging classification to predict renal outcomes in Korean autosomal dominant polycystic kidney disease patients. Kidney Res Clin Pract 2022;41:389–392.
crossref pmid pmc pdf
18. Reddy B, Chapman AB. Acute response to tolvaptan in ADPKD: a window to predict long-term efficacy? Am J Kidney Dis 2015;65:811–813.
crossref pmid
19. Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant 2018;33:477–489.
crossref pmid pmc
20. Muto S, Kawano H, Higashihara E, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol 2015;19:867–877.
crossref pmid pdf
21. Torres VE, Gansevoort RT, Perrone RD, et al. Tolvaptan in ADPKD patients with very low kidney function. Kidney Int Rep 2021;6:2171–2178.
crossref pmid pmc
22. Xie X, Cai Q, Guo XY, et al. Effectiveness of tolvaptan in the treatment for patients with autosomal dominant polycystic kidney disease: a meta-analysis. Comb Chem High Throughput Screen 2020;23:6–16.
crossref pmid
23. Naranjo J, Borrego F, Rocha JL, et al. Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease. Front Med (Lausanne) 2022;9:987092.
crossref pmid pmc
24. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018;29:2458–2470.
crossref pmid pmc
25. Bennett H, McEwan P, Hamilton K, O’Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. BMC Nephrol 2019;20:136.
crossref pmid pmc pdf
26. Bajwa ZH, Gupta S, Warfield CA, Steinman TI. Pain management in polycystic kidney disease. Kidney Int 2001;60:1631–1644.
crossref pmid
27. Casteleijn NF, Blais JD, Chapman AB, et al. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis 2017;69:210–219.
crossref pmid pmc
28. Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993;22:513–519.
crossref pmid
29. Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2009;4:838–844.
crossref pmid pmc
30. Cheungpasitporn W, Erickson SB, Rule AD, Enders F, Lieske JC. Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations. J Urol 2016;195:1476–1481.
crossref pmid pmc
31. Raina R, Houry A, Rath P, et al. Clinical utility and tolerability of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Drug Healthc Patient Saf 2022;14:147–159.
crossref pmid pmc pdf
32. Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep 2017;2:1132–1140.
crossref pmid pmc
33. Anderegg MA, Dhayat NA, Sommer G, et al. Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptan. Kidney Med 2020;2:162–171.
crossref pmid pmc
34. Torres VE, Chapman AB, Devuyst O, et al. Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2020;16:48–58.
crossref pmid pmc
35. Kramers BJ, Koorevaar IW, Drenth JPH, et al. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int 2020;98:989–998.
crossref pmid
36. Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT. Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis 2019;73:354–362.
pmid
37. Shin J, Lee CH. The roles of sodium and volume overload on hypertension in chronic kidney disease. Kidney Res Clin Pract 2021;40:542–554.
crossref pmid pmc pdf
38. Ko GJ, Kalantar-Zadeh K. How important is dietary management in chronic kidney disease progression? A role for low protein diets. Korean J Intern Med 2021;36:795–806.
crossref pmid pmc
39. Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol 2018;19:157.
crossref pmid pmc pdf
40. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007;50:213–222.
crossref pmid
41. Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 2015;38:1103–1113.
crossref pmid pmc pdf
42. Endo M, Katayama K, Matsuo H, et al. Role of liver transplantation in tolvaptan-associated acute liver failure. Kidney Int Rep 2019;4:1653–1657.
crossref pmid pmc
43. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 2016;31:337–348.
crossref pmid pmc
44. Müller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant 2022;37:825–839.
pmid
45. Bhatt PR, McNeely EB, Lin TE, Adams KF, Patterson JH. Review of tolvaptan’s pharmacokinetic and pharmacodynamic properties and drug interactions. J Clin Med 2014;3:1276–1290.
crossref pmid pmc
46. Torres VE, Higashihara E, Devuyst O, et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol 2016;11:803–811.
crossref pmid pmc
47. Song SH, Oh TR, Choi HS, et al. Hyperuricemia is a risk factor for the progression to end-stage renal disease in minimal change disease. Kidney Res Clin Pract 2021;40:411–418.
crossref pmid pmc pdf
48. Waheed Y, Yang F, Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med 2021;36:1281–1293.
crossref pmid pmc pdf
49. Oguro M, Kogure Y, Hoshino J, et al. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease. J Nephrol 2018;31:961–966.
crossref pmid pdf
50. Higashihara E, Nutahara K, Itoh M, et al. Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD. Kidney Int Rep 2022;7:270–281.
crossref pmid pmc
51. Ong AC, Ashley C, Harris T, et al. Commentary on the NICE Guideline on Tolvaptan for treating autosomal dominant polycystic kidney disease [Internet]. Bristol (UK): UK Kidney Association; c2016 [cited 2022 Dec 1]. Available from: https://ukkidney.org/health-professionals/guidelines/commentary-nice-guideline-tolvaptan-treating-autosomal-dominant. 52. Horie S, Mochizuki T, Muto S, et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol 2016;20:493–509.
crossref pmid pmc pdf
53. Nishio S, Tsuchiya K, Nakatani S, et al. A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020. Clin Exp Nephrol 2021;25:1292–1302.
crossref pmid pdf
54. Alpers DH, Lewis JH, Hunt CM, et al. Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials. Am J Kidney Dis 2023;81:281–293.e.
crossref pmid
55. Casteleijn NF, Zittema D, Bakker SJ, et al. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis? Am J Nephrol 2015;41:248–256.
pmid
56. Grantham JJ, Torres VE. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol 2016;12:667–677.
crossref pmid pmc pdf
57. Michell RH, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans 1979;7:861–865.
crossref pmid pdf
58. Mangoo-Karim R, Uchic ME, Grant M, et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J 1989;3:2629–2632.
crossref pmid pdf
59. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 1997;30:703–709.
crossref pmid
60. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991;252:572–574.
crossref pmid
61. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 1999;24:309–318.
crossref pmid
62. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323–1326.
crossref pmid pdf
63. Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol 2011;6:2499–2507.
pmid pmc

留言 (0)

沒有登入
gif